Depomed's AcuForm platform is based on polymer technology that provides targeted drug delivery for a variety of compounds. Additionally, Depomed has commenced a phase II trial of gabapentin ER in postmenopausal patients with hot flushes. The product is in clinical development for the treatment of postherpetic neuralgia and diabetic neuropathies in the US. Gabapentin ER is based on the company's proprietary AcuForm drug delivery technology, which is part of the Gastric Retention (GR) family of technologies this offers improved drug absorption and bioavailability compared with the existing immediate-release formulation of gabapentin (Neurontin), making gabapentin ER suitable for twice-daily dosing. Gabapentin Extended-Release - Depomed: Gabapentin ER, Gabapentin Gastric Retention, Gabapentin GR.ĭepomed is developing an extended-release (ER) oral formulation of gabapentin, a GABA receptor agonist commonly used for the treatment of epilepsy and seizures, neuropathic pain and hot flushes.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |